6.
Amendola A, Boschini A, Colzani D, Anselmi G, Oltolina A, Zucconi R
. Influenza vaccination of HIV-1-positive and HIV-1-negative former intravenous drug users. J Med Virol. 2001; 65(4):644-8.
DOI: 10.1002/jmv.2085.
View
7.
Wang L, Wang Q, Davis P, Volkow N, Xu R
. Increased risk for COVID-19 breakthrough infection in fully vaccinated patients with substance use disorders in the United States between December 2020 and August 2021. World Psychiatry. 2021; 21(1):124-132.
PMC: 8661963.
DOI: 10.1002/wps.20921.
View
8.
Catalan A, Aymerich C, Bilbao A, Pedruzo B, Perez J, Aranguren N
. Psychosis and substance abuse increase the COVID-19 mortality risk. Psychol Med. 2022; 53(9):4236-4244.
PMC: 9114752.
DOI: 10.1017/S0033291722000976.
View
9.
Juno J, Tan H, Lee W, Reynaldi A, Kelly H, Wragg K
. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat Med. 2020; 26(9):1428-1434.
DOI: 10.1038/s41591-020-0995-0.
View
10.
Gozzi-Silva S, Oliveira L, Alberca R, Pereira N, Yoshikawa F, Pietrobon A
. Generation of Cytotoxic T Cells and Dysfunctional CD8 T Cells in Severe COVID-19 Patients. Cells. 2022; 11(21).
PMC: 9659290.
DOI: 10.3390/cells11213359.
View
11.
Saha S, Chant D, McGrath J
. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?. Arch Gen Psychiatry. 2007; 64(10):1123-31.
DOI: 10.1001/archpsyc.64.10.1123.
View
12.
Swadling L, Diniz M, Schmidt N, Amin O, Chandran A, Shaw E
. Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. Nature. 2021; 601(7891):110-117.
PMC: 8732273.
DOI: 10.1038/s41586-021-04186-8.
View
13.
Batki S, Meszaros Z, Strutynski K, Dimmock J, Leontieva L, Ploutz-Snyder R
. Medical comorbidity in patients with schizophrenia and alcohol dependence. Schizophr Res. 2008; 107(2-3):139-46.
PMC: 2649875.
DOI: 10.1016/j.schres.2008.10.016.
View
14.
He R, Zheng X, Zhang J, Liu B, Wang Q, Wu Q
. SARS-CoV-2 spike-specific T cells exhibit unique responses in infected and vaccinated individuals. Signal Transduct Target Ther. 2023; 8(1):393.
PMC: 10558553.
DOI: 10.1038/s41392-023-01650-x.
View
15.
Dickey B, Normand S, Weiss R, Drake R, Azeni H
. Medical morbidity, mental illness, and substance use disorders. Psychiatr Serv. 2002; 53(7):861-7.
DOI: 10.1176/appi.ps.53.7.861.
View
16.
Reece A
. Clinical implications of addiction related immunosuppression. J Infect. 2008; 56(6):437-45.
DOI: 10.1016/j.jinf.2008.03.003.
View
17.
Malone B, Simovski B, Moline C, Cheng J, Gheorghe M, Fontenelle H
. Artificial intelligence predicts the immunogenic landscape of SARS-CoV-2 leading to universal blueprints for vaccine designs. Sci Rep. 2020; 10(1):22375.
PMC: 7758335.
DOI: 10.1038/s41598-020-78758-5.
View
18.
Hjorthoj C, Sturup A, McGrath J, Nordentoft M
. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry. 2017; 4(4):295-301.
DOI: 10.1016/S2215-0366(17)30078-0.
View
19.
Vai B, Mazza M, Delli Colli C, Foiselle M, Allen B, Benedetti F
. Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: a systematic review and meta-analysis. Lancet Psychiatry. 2021; 8(9):797-812.
PMC: 8285121.
DOI: 10.1016/S2215-0366(21)00232-7.
View
20.
Federico L, Malone B, Tennoe S, Chaban V, Osen J, Gainullin M
. Experimental validation of immunogenic SARS-CoV-2 T cell epitopes identified by artificial intelligence. Front Immunol. 2023; 14:1265044.
PMC: 10691274.
DOI: 10.3389/fimmu.2023.1265044.
View